中国临床保健杂志2016，Vol.19Issue(6)：618-621,4.DOI:10.3969/J.issn.1672-6790.2016.06.017
白蛋白结合型紫杉醇联合卡铂和贝伐单抗作为非小细胞肺癌一线方案的疗效和安全性研究
The effect and safety of the combination treatment of nab-paclitaxel,carboplatin and bevacizumab as the first line on non-small cell lung cancer
毕金玲 1刘海渊 1丁露 1姚荣杰 1孟曼 1王为民 1夏云红1
作者信息
- 1. 安徽合肥市第二人民医院肿瘤内科，230011
- 折叠
摘要
Abstract
Objective To explore the effect and safety of the combination treatment of albumin bound paclitax-el,carboplatin and bevacizumab as first line therapy for non-small cell lung cancer (NSCLC).Method A total of 120 patients with NSCLC were randomly divided into control group (60 cased treatment with paclitaxel +carboplatin)and treatment group (60 cases treatment with albumin bound paclitaxel +carboplatin +bevacizumab),The major endpoints were safety and tolerance and the secondary endpoints were progression-free survival (PFS),objective response rate (ORR)and clinical benefit rate (CBR).Results In the control group,PFS was 5.6 months,CBR was 76% and ORR was 67%,while in the treatment group these were 8.9 months,92% and 87%,respectively.Adverse reactions in control group were myelosuppression with III grade (53.4%)and gastrointestinal reaction (46.1%),respectively.These reac-tions in treatment group were 46.9% and 20.1%.Conclusion Compared with traditional treatment of paclitaxel and cisplatin,the combination treatment of albumin bound paclitaxel,carboplatin and bevacizumab is safe and well-tolerated for patients with NSCLC as the first line therapy.关键词
癌,非小细胞肺/药物疗法,联合/紫杉烷类/卡铂Key words
Carcinoma,non-small-cell lung/Drug therapy,combination/Taxoids/Carboplation分类
医药卫生引用本文复制引用
毕金玲,刘海渊,丁露,姚荣杰,孟曼,王为民,夏云红..白蛋白结合型紫杉醇联合卡铂和贝伐单抗作为非小细胞肺癌一线方案的疗效和安全性研究[J].中国临床保健杂志,2016,19(6):618-621,4.
